home > ict > summer 2012 > outsourcing strategies
International Clinical Trials

Outsourcing Strategies

Partnering with Central Labs, ECG and Imaging Labs Outsourcing Strategies Graham Hughes reports from Partnering with Central Labs, ECG and Imaging Labs – an Informa Life Sciences Conference held in Brussels.

The ninth annual event in this series of thought-provoking conferences, organised by Informa Life Sciences in Brussels on the 23rd-24th May 2012, got off to a difficult start. Presenters were forced to cancel at the last moment or, in the case of one presenter, failed to catch the right flight in order to make his presentation. Thus, the conference agenda was rendered a little disjointed.

Day one’s keynote speaker, Chuck Cooper from the FDA, provided an interesting update on the FDA’s policy regarding the use of electronic data and standardised data submissions. He noted that the standardised data format, CDISC, is now being used for some 50 per cent of submissions, but also pointed out that it is not yet a requirement of the FDA – and indeed may never be so. I recall an FDA presentation in the early 1990s, which forecast that, by the year 2000, all submissions would be in electronic format. However, this prediction has proved false, and Cooper was unsure when, if ever, the FDA would make this a requirement.

Simon Harper, a lawyer from Eli Lilly, discussed the recent UK legislation in anti-bribery as it applied to clinical trials. This law has widespread implications for pharmaceutical organisations, and will require companies to assess risks, do due diligence on their clients, communicate their policies to their staff and monitor and review what is actually happening within their organisation in respect to bribery. Interpreted strictly, the law may mean that it would be illegal in the UK to buy an individual investigator as little as a coffee or a sandwich, but it is possible to give a presentation to a group of doctors taking part in the clinical trial.

A panel discussion of the challenges to the central laboratory industries noted the following factors:

  • Biomarkers and large molecules
  • Emerging countries
  • The importance of cost reduction
  • A lack of preferred provider relationships with individual laboratories
  • Personalised medicine
  • Translation of biomarkers into diagnostics

China is changing its legislation in relation to clinical trials and particularly central laboratories. Details of this, and how to conduct business in China, were discussed by Labcorp’s Marleen Hereygers and the godfather of the outsourcing industry, Stephen Porter. Guy Mascaro from the Metrics Champion Consortium gave a teleconference from the organisation’s headquarters in the US. This worked surprisingly well, and he shared a great deal of useful information on how the MCC is developing.

On day two, there was an interesting panel discussion and group work session which discussed the relationships between providers and their clients. The discussion centred around trust, communications and micromanagement, and urged participants to be honest, proactive, transparent and to attribute no blame to their suppliers or their clients. Olivier Simon of Biomedical Systems noted that pathology is now becoming increasingly digitalised. Professor Elke Smits of the Antwerp University Clinical Research Centre discussed how academics needed to bridge the gap between themselves and the industry in order to make the most of the technology available in universities.

In another session, James Denmark showed a video from Daniel Pink which discussed motivation performance and success in clinical trials. Richard Barrett, an independent consultant, noted that the Achilles heel of clinical research is its handling of logistics. He felt that there may be a need for more on-site labs in bigger trial sites, and noted that there were always hidden internal costs in the use of outsourced laboratories, especially if there were numerous local or national laboratories involved in the trial. He further noted that the quality of data is generally not an issue with laboratories, and neither is the combination of data from various labs.

As usual, the conference was well organised by Informa in spite of their difficulties with speakers, and it is with regret that we say goodbye to Siobhan Corry, who is leaving Informa to return to her native Australia.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.


Graham Hughes
Print this page
Send to a friend
Privacy statement
News and Press Releases

Joining forces against SARS-CoV-2

Laupheim, Germany and Milford, MA, USA, October 08, 2020 - Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced an agreement to serve as CDMO partner for BioNTech. As an initial project, Rentschler Biopharma will be responsible for key aspects of cGMP (current good manufacturing practice) drug substance manufacturing of BNT162b2, the mRNA-based vaccine against SARS-CoV-2 that is being developed by Pfizer and BioNTech, and is currently in a global Phase 3 clinical trial.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement